Cargando…

No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC

SIMPLE SUMMARY: High tumor-infiltrating lymphocyte (TIL) levels are associated with an increased response to neoadjuvant chemotherapy (NAC) in breast cancer (BC). The seasonal fluctuation of TILs in breast cancer is poorly documented. In this study, we compared pre- and post-treatment immune infiltr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grandal, Beatriz, Aljehani, Ashwaq, Dumas, Elise, Daoud, Eric, Jochum, Floriane, Gougis, Paul, Hotton, Judicaël, Lemoine, Amélie, Michel, Sophie, Laas, Enora, Laé, Marick, Pierga, Jean-Yves, Alaoui Ismaili, Khaoula, Lerebours, Florence, Reyal, Fabien, Hamy, Anne Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264787/ https://www.ncbi.nlm.nih.gov/pubmed/35804852 http://dx.doi.org/10.3390/cancers14133080

Ejemplares similares

Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns
por: Gougis, Paul, et al.
Publicado: (2023)

Effects of gender and socio-environmental factors on health-care access in oncology: a comprehensive, nationwide study in France
por: Jochum, Floriane, et al.
Publicado: (2023)

The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)
por: Dumas, Elise, et al.
Publicado: (2022)

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy
por: Hamy, Anne-Sophie, et al.
Publicado: (2020)

The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes
por: Laot, Lucie, et al.
Publicado: (2021)

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy
por: Grandal, Beatriz, et al.
Publicado: (2021)

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up Consultation
por: Nicolas, Marion, et al.
Publicado: (2021)

The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer
por: Labrosse, Julie, et al.
Publicado: (2021)

Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
por: Laas, Enora, et al.
Publicado: (2021)

Impact of the Area of Residence of Ovarian Cancer Patients on Overall Survival
por: Jochum, Floriane, et al.
Publicado: (2022)

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis
por: Labrosse, Julie, et al.
Publicado: (2020)

Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach
por: Laas, Enora, et al.
Publicado: (2019)

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
por: Laas, Enora, et al.
Publicado: (2021)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Grandal, Beatriz, et al.
Publicado: (2020)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer Patients
por: Labrosse, Julie, et al.
Publicado: (2021)

Evolution of synchronous female bilateral breast cancers and response to treatment
por: Hamy, Anne-Sophie, et al.
Publicado: (2023)

Interactive exploration of a global clinical network from a large breast cancer cohort
por: Sella, Nadir, et al.
Publicado: (2022)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
por: Gosset, Marie, et al.
Publicado: (2016)

Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
por: Hours, Alice, et al.
Publicado: (2021)

Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial
por: Delrieu, Lidia, et al.
Publicado: (2022)

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
por: Rossi, L, et al.
Publicado: (2015)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application
por: Laas, Enora, et al.
Publicado: (2016)

Sentinel Lymph Node Biopsy in Uterine Cancer: Time for a Modern Approach
por: Laas, Enora, et al.
Publicado: (2023)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population
por: Rossi, Lea, et al.
Publicado: (2015)

Neoadjuvant treatment: the future of patients with breast cancer
por: Reyal, F, et al.
Publicado: (2018)

How to perform sentinel node detection in high-risk endometrial cancer: one step forward
por: Balaya, Vincent, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data
por: Abécassis, Judith, et al.
Publicado: (2019)

Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
por: Bidard, François-Clément, et al.
Publicado: (2013)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways
por: Laé, Marick, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_usggppimpfp5a9h984mfnksifj